Clinical Trial

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
Protocol Amendment History 4 changes
critical Recruitment opened 2026-07-22
notable Enrollment increased: 425 -> 675 participants 2026-07-22
notable Primary completion pushed: 2027-07 -> 2027-10-31 2026-07-22
minor Completion pushed: 2027-08 -> 2027-11-30 2026-07-22
Trial Details
NCT Number NCT07670884
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Chronic Management of Body Weight
Enrollment 675 participants
Start Date 2026-07-24
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-13